This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Next step in expansion of TOSP with detailed planning application submitted for Plot 27

Next step in expansion of TOSP with detailed planning application submitted for Plot 27

14 Nov 2022

Next step in expansion of TOSP with detailed planning application submitted for Plot 27 New R&D building part of >500,000 sq ft expansion plan as the Park innovation ecosystem grows Oxford, UK, November 14 2022 –The Oxford Science Park (TOSP), one of Europe's leading locations for science and technology companies, is delighted to announce the next step in its development plan with the submission of a detailed planning application for a new... Read more

Jérôme Marzinski appointed as Chief Executive Officer

Jérôme Marzinski appointed as Chief Executive Officer

07 Nov 2022

Seasoned medtech leader with a proven track record in scaling companies Oxford, UK – 7 November 2022 – OxSonics Therapeutics, a clinical-stage company focused on transforming cancer treatment through SonoTran®, its ultrasound-based drug delivery platform, announces that it has appointed Jérôme Marzinski as its Chief Executive Officer with immediate effect. Jérôme is a seasoned medtech leader, having held a variety of senior roles over a... Read more

OxSonics presents preclinical data demonstrating SonoTran® enhanced the delivery and efficacy of an oncolytic virus in a murine bladder cancel model

OxSonics presents preclinical data demonstrating SonoTran® enhanced the delivery and efficacy of an oncolytic virus in a murine bladder cancel model

25 Oct 2022

OxSonics presents preclinical data demonstrating SonoTran® enhanced the delivery and efficacy of an oncolytic virus in a murine bladder cancel model Data presented at the International Oncolytic Virus Conference (IOVC) from a collaboration with Turnstone Biologics. Oxford, UK – 25 October 2022 – OxSonics Therapeutics, a clinical-stage company focused on transforming cancer treatment through SonoTran®, its ultrasound-based drug delivery... Read more

Scancell signs Commercial License Agreement with Genmab

Scancell signs Commercial License Agreement with Genmab

25 Oct 2022

Scancell Holdings plc ("Scancell" or the "Company") Scancell signs Commercial License Agreement with Genmab Genmab granted worldwide license to anti-glycan monoclonal antibody generated via Scancell's proprietary GlyMab® platform, for the development and commercialisation of novel therapeutic products Scancell to receive from Genmab an upfront payment as well as potential milestone payments of up to $208 million for each product... Read more

Nucleome Tx raises £37.5m Series A to decode dark matter of genome & deliver first-in-class drugs

Nucleome Tx raises £37.5m Series A to decode dark matter of genome & deliver first-in-class drugs

19 Oct 2022

Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines • Financing led by M Ventures alongside other new investors JJDC, Pfizer Ventures and British Patient Capital, and including founding investor Oxford Science Enterprises • Nucleome’s pioneering platform seeks to identify direct genetic linkages to disease-associated genes... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More